AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19251144 — intervention group
Group type: COMPARATOR
Intervention: Tecnis Z9000 IOL with negative spherical aberration (negative‐aberration IOL group)
Number of subjects: 0
Study 19251144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ADVS score
Number of subjects: 0
Study 17984346 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 73
Study 17984346 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 73
Study 17984346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rifampin and azithromycin
Number of subjects: 73
Study 17984346 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins (Control)
Number of subjects: 73
Study 15213322 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-buffered PD fluid
Number of subjects: 14
Study 15213322 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD fluid
Number of subjects: 14
Study 11694608 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triacylglycerols (MCT)
Number of subjects: 78
Study 11694608 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCT)
Number of subjects: 78
Study 7525633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg BW.day recombinant human GH (rhGH)
Number of subjects: 18
Study 7525633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3037812 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4256 vaccine in adults
Number of subjects: 80
Study 3037812 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4256 vaccine in 6-month-old children
Number of subjects: 80
Study 3037812 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4256 vaccine in newborn infants
Number of subjects: 80
Study 3037812 — intervention group
Group type: COMPARATOR
Intervention: RIT 4237 vaccine in newborn infants
Number of subjects: 80
Study 3037812 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RIT 4256 and RIT 4237 vaccines
Number of subjects: 80
Study 30260251 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL/kg of 3% HS (group L)
Number of subjects: 60
Study 30260251 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL/kg of 3% HS (group H)
Number of subjects: 60
Study 27165280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Number of subjects: 45
Study 27165280 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 45
Study 27165280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg
Number of subjects: 45
Study 27165280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg and 5 mg
Number of subjects: 45
Study 24892197 — intervention group
Group type: COMPARATOR
Intervention: VRC (pain control)
Number of subjects: 77
Study 24892197 — intervention group
Group type: COMPARATOR
Intervention: VRD (distraction)
Number of subjects: 77
Study 22112395 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical range symptoms on the attention problems scale of the CBCL
Number of subjects: 168
Study 22112395 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical range symptoms on the anxious/depressed scale of the CBCL
Number of subjects: 168
Study 22112395 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive behavior symptoms (measured by CBCL)
Number of subjects: 168
Study 22112395 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive behavior
Number of subjects: 168
Study 20724648 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg alogliptin plus 30 mg pioglitazone (A25+P30)
Number of subjects: 655
Study 20724648 — intervention group
Group type: COMPARATOR
Intervention: 25 mg alogliptin (A25)
Number of subjects: 655
Study 20724648 — intervention group
Group type: COMPARATOR
Intervention: 30 mg pioglitazone (P30)
Number of subjects: 655
Study 18772723 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline (active control)
Number of subjects: 11
Study 18772723 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous marketed artificial tear formulations (test formulation)
Number of subjects: 11
Study 16260342 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (0.4 mg)
Number of subjects: 97
Study 16260342 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (0.8 mg)
Number of subjects: 97
Study 12106840 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity leg exercise (three 30-minute sessions/week) for 10 weeks
Number of subjects: 58
Study 12106840 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (control group)
Number of subjects: 58
Study 10074978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology plus cervicography
Number of subjects: 5550
Study 10074978 — intervention group
Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 5550
Study 7674700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen solution (25 mg)
Number of subjects: 16
Study 7674700 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen tablet (2.5 mg)
Number of subjects: 16
Study 7674700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 16
Study 7674700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen solution
Number of subjects: 16
Study 2035779 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask anaesthesia
Number of subjects: 50
Study 2035779 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask anaesthesia
Number of subjects: 50
Study 7012668 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol therapy
Number of subjects: 0
Study 7012668 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 31104280 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg netupitant/0.5 mg palonosetron
Number of subjects: 30
Study 29600390 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised technology-based levodopa monitoring
Number of subjects: 20
Study 29600390 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised technology-based levodopa monitoring
Number of subjects: 20
Study 26773983 — intervention group
Group type: EXPERIMENTAL
Intervention: Early spinal decompression (≤24 hours since trauma)
Number of subjects: 0
Study 26773983 — intervention group
Group type: COMPARATOR
Intervention: Delayed spinal decompression
Number of subjects: 0
Study 24570327 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) intravenous infusion of 20 ng/kg/min for 6 hours before and after contrast media administration
Number of subjects: 163
Study 24570327 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution for routine hydration (control group)
Number of subjects: 163
Study 22024226 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN a-2b/RBV therapy (Secondary IFN group)
Number of subjects: 54
Study 22024226 — intervention group
Group type: COMPARATOR
Intervention: Non-secondary IFN group (Control)
Number of subjects: 54
Study 19195791 — intervention group
Group type: EXPERIMENTAL
Intervention: AVPR1a RS3 repeat length
Number of subjects: 113
Study 19195791 — intervention group
Group type: EXPERIMENTAL
Intervention: AVPR1a RS1 and RS3 polymorphisms
Number of subjects: 113
Study 19195791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex x RS3 interaction
Number of subjects: 113
Study 17223306 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous iliofascial nerve sheath block (KT group) with 30 ml of ropivacaïne 4.75 mg/ml and 14 mg/h of ropivacaïne 2 mg/ml for 48 hours
Number of subjects: 21
Study 17223306 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous iliofascial nerve sheath block (KT group)
Number of subjects: 21
Study 17223306 — intervention group
Group type: COMPARATOR
Intervention: Control group (NKT) with no iliofascial block
Number of subjects: 21
Study 17223306 — intervention group
Group type: COMPARATOR
Intervention: Control group (NKT)
Number of subjects: 21
Study 16753936 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve-sparing operations (David I reimplantation technique, Gel-weave Valsalva graft)
Number of subjects: 85
Study 16753936 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve-sparing operations
Number of subjects: 85
Study 12648174 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol initially then a further identical dose 6 h later
Number of subjects: 191
Study 12648174 — intervention group
Group type: COMPARATOR
Intervention: 2 mg dinoprostone initially followed by 1 mg 6 h later
Number of subjects: 191
Study 12648174 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg misoprostol
Number of subjects: 191
Study 12648174 — intervention group
Group type: COMPARATOR
Intervention: 2 mg dinoprostone
Number of subjects: 191
Study 12648174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 191
Study 10686630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve mother-child interaction
Number of subjects: 38
Study 10686630 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 38
Study 10686630 — intervention group
Group type: COMPARATOR
Intervention: Cerebral palsy and developmental delays
Number of subjects: 38
Study 8842782 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg initial dose followed by 20 mg tid for 5 days)
Number of subjects: 169
Study 8842782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no trimetazidine)
Number of subjects: 169
Study 1495860 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1,000 micrograms daily
Number of subjects: 24
Study 1495860 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 asthmatic children)
Number of subjects: 24
Study 6406654 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine IV, 10 mg/kg . day
Number of subjects: 29
Study 6406654 — intervention group
Group type: COMPARATOR
Intervention: No supplement (Control)
Number of subjects: 29
Study 31189564 — intervention group
Group type: EXPERIMENTAL
Intervention: CoYoT1 (shared telemedicine appointments)
Number of subjects: 42
Study 31189564 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study 29463485 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Bed Exercise (SBE)
Number of subjects: 45
Study 29463485 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 26902504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (FF) and vilanterol (VI) combination therapy
Number of subjects: 0
Study 26902504 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fluticasone furoate (FF)
Number of subjects: 0
Study 26902504 — intervention group
Group type: COMPARATOR
Intervention: Inhaled vilanterol (VI)
Number of subjects: 0
Study 24472827 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-specific Compensatory Health Beliefs (CHBs)
Number of subjects: 75
Study 21385217 — intervention group
Group type: EXPERIMENTAL
Intervention: Slackline training (10 sessions)
Number of subjects: 24
Study 21385217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 20662916 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 13
Study 20662916 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (control group)
Number of subjects: 13
Study 17379475 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin 20%
Number of subjects: 68
Study 17379475 — intervention group
Group type: COMPARATOR
Intervention: Polygeline
Number of subjects: 68
Study 15692889 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone for one month (first week) and topical fluormetalone for the next three weeks
Number of subjects: 210
Study 15692889 — intervention group
Group type: COMPARATOR
Intervention: Topical dexamethasone for one week
Number of subjects: 210
Study 12458395 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium (Tl)
Number of subjects: 2560
Study 12458395 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyisobutylisonitrile (MIBI)
Number of subjects: 2560
Study 12458395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrofosmin (Tf)
Number of subjects: 2560
Study 10204949 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 35
Study 10204949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 35
Study 10204949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 7575117 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified follow-up
Number of subjects: 106
Study 7575117 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 106
Study 2267266 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Number of subjects: 28
Study 7028533 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (25 mg for ages 2-5 years; 50 mg for ages 6-10 years)
Number of subjects: 43
Study 7028533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31541518 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 391
Study 28062862 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS
Number of subjects: 123
Study 28062862 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS
Number of subjects: 123
Study 28062862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation
Number of subjects: 123
Study 28062862 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current stimulation
Number of subjects: 123
Study 28062862 — intervention group
Group type: EXPERIMENTAL
Intervention: Diadynamic current
Number of subjects: 123
Study 28062862 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 25614155 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg/day plus Serenoa repens 320 mg/day
Number of subjects: 140
Study 25614155 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg/day only
Number of subjects: 140
Study 25614155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 23617610 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus(®) cochlear implant fitting suite
Number of subjects: 37
Study 23617610 — intervention group
Group type: COMPARATOR
Intervention: Custom Sound™ methodology
Number of subjects: 37
Study 21508862 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (2 weeks and 4 weeks duration)
Number of subjects: 22
Study 21508862 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated schizophrenia patients
Number of subjects: 22
Study 21508862 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 22
Study 19825324 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone immediate-release (IR) 1 mg dose
Number of subjects: 20
Study 16869814 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of cefotaxime (2 g over 24 h plus a loading dose of 1 g)
Number of subjects: 93
Study 16869814 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of cefotaxime (1 g three times daily)
Number of subjects: 93
Study 15200652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.4%, 2 mg x kg(‐1))
Number of subjects: 99
Study 15200652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.2%, 1 mg x kg(‐1)) plus ketamine (0.25 mg x kg(‐1))
Number of subjects: 99
Study 15200652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.2%, 1 mg x kg(‐1)) plus tramadol (1 mg x kg(‐1))
Number of subjects: 99
Study 15200652 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ropivacaine alone)
Number of subjects: 99
Study 11158224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 12
Study 11158224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 12
Study 9549662 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 1.5 mg/kg, MD = 0.25 mg/kg)
Number of subjects: 27
Study 9549662 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 2.5 mg/kg, MD = 0.40 mg/kg)
Number of subjects: 27
Study 9549662 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 4.0 mg/kg, MD = 0.65 mg/kg)
Number of subjects: 27
Study 9549662 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 4.0 mg/kg, MD = 1.0 mg/kg)
Number of subjects: 27
Study 9549662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 9549662 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (highest doses)
Number of subjects: 27
Study 8092543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg/day
Number of subjects: 101
Study 8092543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 3381993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine
Number of subjects: 124
Study 3381993 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg fentanyl
Number of subjects: 124
Study 3381993 — intervention group
Group type: COMPARATOR
Intervention: Thiopental alone
Number of subjects: 124
Study 30205708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 149
Study 30205708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 149
Study 27939089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A: 12-session treatment program including discussion of low back pain experience, graded sensory training, graded motor imagery training, and functional movement training.
Number of subjects: 275
Study 27939089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B: 12-session treatment program including discussion of low back pain experience, transcranial direct current stimulation, cranial electrical stimulation, low-intensity laser therapy, and pulsed electromagnetic energy.
Number of subjects: 275
Study 27939089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A and B (both interventions).
Number of subjects: 275
Study 25534866 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day simvastatin
Number of subjects: 30
Study 25534866 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg/day
Number of subjects: 30
Study 25534866 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 30
Study 23254319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic screening in patients with recalled Riata leads
Number of subjects: 48
Study 22088245 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg/d) plus Irbesartan (150 mg/d)
Number of subjects: 123
Study 22088245 — intervention group
Group type: COMPARATOR
Intervention: Felodipine (5 mg/d) plus Metoprolol (47.5 mg/d)
Number of subjects: 123
Study 17400311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0
Study 17400311 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study 17069060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronoran
Number of subjects: 70
Study 17069060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12858321 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 0
Study 12858321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14506194 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In‐ITC‐DTPA‐cG250
Number of subjects: 5
Study 14506194 — intervention group
Group type: COMPARATOR
Intervention: 131I‐cG250
Number of subjects: 5
Study 10202987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sib pairs with MS
Number of subjects: 51
Study 10202987 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent/child pairs with MS
Number of subjects: 51
Study 10202987 — intervention group
Group type: COMPARATOR
Intervention: Genomic analysis of TNF loci
Number of subjects: 51
Study 10202987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sib pair analysis using TNF haplotypes
Number of subjects: 51
Study 7636648 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine (booster dose)
Number of subjects: 350
Study 2794204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate at 40 meq/L
Number of subjects: 0
Study 2794204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate at 100 meq/L
Number of subjects: 0
Study 2794204 — intervention group
Group type: COMPARATOR
Intervention: 0 meq/L sodium bicarbonate
Number of subjects: 0
Study 2794204 — intervention group
Group type: COMPARATOR
Intervention: 10 meq/L sodium bicarbonate
Number of subjects: 0
Study 797547 — intervention group
Group type: EXPERIMENTAL
Intervention: Halcinonide cream
Number of subjects: 59
Study 797547 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide cream
Number of subjects: 59
Study 31685356 — intervention group
Group type: EXPERIMENTAL
Intervention: Early restrictive fluid resuscitation (EFR)
Number of subjects: 174
Study 28115256 — intervention group
Group type: EXPERIMENTAL
Intervention: Request for Hong Kong Identity Card number (HKID)
Number of subjects: 1200
Study 28115256 — intervention group
Group type: EXPERIMENTAL
Intervention: Souvenir incentive (valued at USD4)
Number of subjects: 1200
Study 28115256 — intervention group
Group type: COMPARATOR
Intervention: No request for HKID
Number of subjects: 1200
Study 28115256 — intervention group
Group type: COMPARATOR
Intervention: No souvenirs
Number of subjects: 1200
Study 25959848 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sepsis bundle group (ISBG)
Number of subjects: 105
Study 25959848 — intervention group
Group type: COMPARATOR
Intervention: Conventional sepsis bundle group
Number of subjects: 105
Study 24004682 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored home hazard reduction and balance and strength exercise fall prevention program
Number of subjects: 22
Study 24004682 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 22
Study 21334626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (nutrition education, exercise therapy, psychological care)
Number of subjects: 27
Study 21334626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 27